Solara Active Pharma Sciences Receives ₹129.94 Crore in Final Call Money
Solara Active Pharma Sciences received ₹129.94 crore from the second and final call on rights equity shares. The company approved converting 1.15 crore partly paid-up shares into fully paid-up shares with a face value of ₹10 each.
The receipt of call money for rights equity shares is a procedural step in a previously announced fundraising activity. It does not introduce new information that is likely to cause a significant market reaction.
The announcement reports the successful collection of funds related to a rights issue, which is a standard financial procedure. It does not contain information that would significantly alter the company's valuation or future prospects in a positive or negative manner.
Solara Active Pharma Sciences Limited has announced the receipt of call money in respect of the Second & Final Call on its Rights Equity Shares. The company received an aggregate amount of ₹1,29,94,28,775.00 (Rupees One Hundred and Twenty-Nine Crores Ninety-Four Lakhs Twenty-Eight Thousand Seven Hundred and Seventy-Five Only).
This amount comprises payments for 1,15,50,478 Rights equity shares, each called at ₹112.50. The Rights Issue Committee of the Board of Directors, in its meeting held on May 15, 2026, approved the conversion of these 1,15,50,478 partly paid-up equity shares into fully paid-up equity shares. These converted shares will have a face value of ₹10.00 each with ₹10.00 paid-up, bearing ISIN INE624Z01016.
The company stated it will undertake the necessary steps to obtain listing and trading approvals for these converted shares. As of the announcement date, the company's paid-up capital stands at ₹47,98,12,464.50, consisting of 4,77,25,485 fully paid-up equity shares and partly paid-up shares.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.